Annaliesa S. Anderson

Pfizer (United States) — United States

Medicine · Health Sciences

52h-index11.8kcitations255works6.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pneumonia and Respiratory Infections(70), Bacterial Infections and Vaccines(64), SARS-CoV-2 and COVID-19 Research(51), Antimicrobial Resistance in Staphylococcus(48), Respiratory viral infections research(36)

Publications255 total

Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine–naive adults ≥18 years of age in India: A phase 3 single-arm trial
Human Vaccines & Immunotherapeutics·2026· 1 citedOpen Access
Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine
2025Open Access
Genotypic and phenotypic comparison of <i>Neisseria meningitidis</i> carriage and invasive disease isolates contemporaneously collected in the Netherlands
FEMS Microbiology Letters·2025Open Access
Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines
Nature Communications·2025· 1 citedOpen Access
Genomic characterization of clinical Borrelia burgdorferi sensu lato isolates in the Netherlands over a thirty-year period
BMC Genomics·2025Open Access
Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine
New England Journal of Medicine·2025· 7 cited
Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine
NEJM Evidence·2025· 2 cited
DISSEMINATED MYCOBACTERIAL INFECTION IN THE SETTING OF IDIOPATHIC CD4 LYMPHOCYTOPENIA
CHEST Journal·2025
Mouse monoclonal antibodies against <i>Clostridioides difficile</i> toxins TcdA and TcdB target diverse epitopes for neutralization
Infection and Immunity·2025Open Access
Integrated Analysis of the Safety Experience in Adults with the Bivalent Respiratory Syncytial Virus Prefusion F Vaccine
Vaccines·2025· 1 citedOpen Access
Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques
Science Translational Medicine·2025· 5 cited
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial
Infectious Diseases and Therapy·2025· 1 citedOpen Access
Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1/2 randomised controlled trial
The Lancet Infectious Diseases·2025· 4 cited
Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine: Correction
Obstetrics and Gynecology·2025
A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults
Vaccines·2025· 4 citedOpen Access
Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults
Vaccines·2025· 6 citedOpen Access
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease
Journal of Medicinal Chemistry·2025· 15 cited
A Phase 2b Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 6-Valent Group B <i>Streptococcus</i> Vaccine Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine in Healthy Nonpregnant Female Individuals
The Journal of Infectious Diseases·2025· 7 citedOpen Access
Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial
Human Vaccines & Immunotherapeutics·2025· 2 citedOpen Access
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old
Vaccine·2025· 5 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Kathrin U. Jansen(19), Kathrin U. Jansen(13), David Cooper(10), William C. Gruber(8), Lisa K. McNeil(8), Shannon L. Harris(7), Thomas R. Jones(7), Ingrid L. Scully(7), James Baber(6), Gary W. Zlotnick(6), John L. Perez(6), David Radley(5), Peter Richmond(5), Alejandra Gurtman(5), Qin Jiang(5), Ellen Murphy(5), Joseph Eiden(5), Douglas Girgenti(5), Robert G. K. Donald(5), Eugene P. Kadar(4)